Statistics in Biopharmaceutical Research

Papers
(The H4-Index of Statistics in Biopharmaceutical Research is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Composite Endpoints in Cardio-Renal Clinical Outcome Trials26
DODII: Bayesian Dose Optimization Design for Randomized Phase II Trials19
Predicting Probability of Success for Phase III Trials via Propensity-Score-Based External Data Borrowing19
U-MET: Utility-Based Dose Optimization Approach for Multiple-Dose Randomized Trial Designs17
Use of Nonconcurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion15
Statistical Inference of the Probability of Passing the USP Dissolution Test14
Some Multiplicity Adjustment Procedures for Clinical Trials with Sequential Design and Multiple Endpoints13
Modified Simon’s Two-Stage Design for Phase IIA Clinical Trials in Oncology—Dynamic Monitoring and More Flexibility11
Consistency Based Multiplicity Adjustment Approach—Multiple Doses in Phase III Studies11
We Need Subject Matter Expertise to Choose and Identify Causal Estimands: Comment on “Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event”9
Missing Data Imputation for a Multivariate Outcome of Mixed Variable Types9
The current landscape of HTA framework and key challenges9
A Basket Trial Design Based on Power Priors9
0.021474838256836